MX2014012742A - Composicion para el tratamiento de transtornos metabólicos. - Google Patents

Composicion para el tratamiento de transtornos metabólicos.

Info

Publication number
MX2014012742A
MX2014012742A MX2014012742A MX2014012742A MX2014012742A MX 2014012742 A MX2014012742 A MX 2014012742A MX 2014012742 A MX2014012742 A MX 2014012742A MX 2014012742 A MX2014012742 A MX 2014012742A MX 2014012742 A MX2014012742 A MX 2014012742A
Authority
MX
Mexico
Prior art keywords
composition
treatment
metabolic disorders
relates
extract
Prior art date
Application number
MX2014012742A
Other languages
English (en)
Spanish (es)
Inventor
Arvind Saklani
Parikshit Gaikwad
Malpure Nilesh
Satish Namdeo Sawant
Tukaram Kisanrao Mane
Somesh Sharma
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of MX2014012742A publication Critical patent/MX2014012742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2014012742A 2012-04-23 2013-04-22 Composicion para el tratamiento de transtornos metabólicos. MX2014012742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636792P 2012-04-23 2012-04-23
PCT/IB2013/053155 WO2013160811A1 (en) 2012-04-23 2013-04-22 Composition for treating metabolic disorders

Publications (1)

Publication Number Publication Date
MX2014012742A true MX2014012742A (es) 2015-04-08

Family

ID=49482298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012742A MX2014012742A (es) 2012-04-23 2013-04-22 Composicion para el tratamiento de transtornos metabólicos.

Country Status (16)

Country Link
US (1) US20150290265A1 (cg-RX-API-DMAC10.html)
EP (1) EP2841080A4 (cg-RX-API-DMAC10.html)
JP (1) JP2015514797A (cg-RX-API-DMAC10.html)
KR (1) KR20150003862A (cg-RX-API-DMAC10.html)
CN (1) CN104244962A (cg-RX-API-DMAC10.html)
AU (1) AU2013254329A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014026326A2 (cg-RX-API-DMAC10.html)
CA (1) CA2870907A1 (cg-RX-API-DMAC10.html)
IL (1) IL235317A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014MN02269A (cg-RX-API-DMAC10.html)
MX (1) MX2014012742A (cg-RX-API-DMAC10.html)
NZ (1) NZ701133A (cg-RX-API-DMAC10.html)
RU (1) RU2014145931A (cg-RX-API-DMAC10.html)
SA (1) SA113340494B1 (cg-RX-API-DMAC10.html)
TW (1) TW201343174A (cg-RX-API-DMAC10.html)
WO (1) WO2013160811A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170368018A1 (en) * 2014-12-19 2017-12-28 Halo Life Science, Llc Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
ES3025460T3 (en) 2017-01-06 2025-06-09 Janssen Pharmaceutica Nv Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
RU2022101021A (ru) 2018-01-10 2022-03-18 Брайтсид, Инк. Способ модуляции метаболизма
EP3768269B1 (en) 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Compounds and uses thereof
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2021096813A1 (en) 2019-11-11 2021-05-20 Brightseed, Inc Extract, consumable product and method for enriching bioactive metabolite in an extract
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
KR102408566B1 (ko) * 2020-04-09 2022-06-16 대한민국 터미날리아 비아라타 추출물을 이용한 피부 주름 개선용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005053864A (ja) * 2003-08-06 2005-03-03 Ryukyu Bio Resource Kaihatsu:Kk 糖尿病疾患予防・治療剤
JP2006188486A (ja) * 2004-12-07 2006-07-20 Toyo Shinyaku:Kk 体脂肪蓄積抑制または低減剤
WO2006090198A2 (en) * 2005-02-23 2006-08-31 Avestha Gengraine Technologies Pvt Ltd. Plant extracts and methods and uses therefore

Also Published As

Publication number Publication date
KR20150003862A (ko) 2015-01-09
TW201343174A (zh) 2013-11-01
CN104244962A (zh) 2014-12-24
CA2870907A1 (en) 2013-10-31
US20150290265A1 (en) 2015-10-15
NZ701133A (en) 2016-08-26
RU2014145931A (ru) 2016-06-20
WO2013160811A1 (en) 2013-10-31
IN2014MN02269A (cg-RX-API-DMAC10.html) 2015-07-24
IL235317A0 (en) 2014-12-31
EP2841080A4 (en) 2015-11-25
JP2015514797A (ja) 2015-05-21
AU2013254329A1 (en) 2014-11-13
EP2841080A1 (en) 2015-03-04
SA113340494B1 (ar) 2015-12-24
BR112014026326A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
MX2014012742A (es) Composicion para el tratamiento de transtornos metabólicos.
CO2018001375A2 (es) Composiciones de retinoides tópicos
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
BR112012023021A2 (pt) compostos de indazol e seus usos
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
MX2016014854A (es) Compuestos y composiciones para inducir condrogenesis.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY37947A (es) Amidas de imidazopiridina sustituidas y su uso
DOP2016000007A (es) Pirazolpiridinas sustituidas
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
MX2014010926A (es) Composicion herbaria para el tratamiento de transtornos metabolicos.
ECSP15025868A (es) Composición que comprende un extracto purificado aíslado de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir/tratar la enfermedad pulmonar obstructiva crónica, y su uso
CO2018011797A2 (es) Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.